Logo image of MRVI

MARAVAI LIFESCIENCES HLDGS-A (MRVI) Stock Fundamental Analysis

NASDAQ:MRVI - US56600D1072 - Common Stock

2.38 USD
+0.05 (+2.15%)
Last: 8/28/2025, 8:27:26 PM
2.38 USD
0 (0%)
After Hours: 8/28/2025, 8:27:26 PM
Fundamental Rating

2

Overall MRVI gets a fundamental rating of 2 out of 10. We evaluated MRVI against 54 industry peers in the Life Sciences Tools & Services industry. The financial health of MRVI is average, but there are quite some concerns on its profitability. MRVI does not seem to be growing, but still is valued expensively.


Dividend Valuation Growth Profitability Health

Quickly go to:

1

1. Profitability

1.1 Basic Checks

In the past year MRVI has reported negative net income.
In the past year MRVI has reported a negative cash flow from operations.
In multiple years MRVI reported negative net income over the last 5 years.
MRVI had a positive operating cash flow in each of the past 5 years.
MRVI Yearly Net Income VS EBIT VS OCF VS FCFMRVI Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2018 2019 2020 2021 2022 2023 2024 0 200M 400M

1.2 Ratios

MRVI's Return On Assets of -21.71% is on the low side compared to the rest of the industry. MRVI is outperformed by 70.37% of its industry peers.
The Return On Equity of MRVI (-73.24%) is worse than 75.93% of its industry peers.
Industry RankSector Rank
ROA -21.71%
ROE -73.24%
ROIC N/A
ROA(3y)-4.24%
ROA(5y)0.56%
ROE(3y)-10.9%
ROE(5y)22.38%
ROIC(3y)N/A
ROIC(5y)N/A
MRVI Yearly ROA, ROE, ROICMRVI Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2018 2019 2020 2021 2022 2023 2024 0 20 -20 40 -40 60 80

1.3 Margins

MRVI has a worse Gross Margin (29.11%) than 72.22% of its industry peers.
In the last couple of years the Gross Margin of MRVI has declined.
MRVI does not have Profit Margin and Operating Margin available, so we won't be analyzing them here.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM 29.11%
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-20.26%
GM growth 5Y-4.76%
MRVI Yearly Profit, Operating, Gross MarginsMRVI Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2018 2019 2020 2021 2022 2023 2024 0 20 -20 40 -40 60 80

More info and screens

4

2. Health

2.1 Basic Checks

MRVI does not have a ROIC to compare to the WACC, probably because it is not profitable.
Compared to 1 year ago, MRVI has more shares outstanding
MRVI has less shares outstanding than it did 5 years ago.
The debt/assets ratio for MRVI has been reduced compared to a year ago.
MRVI Yearly Shares OutstandingMRVI Yearly Shares OutstandingYearly Shares Outstanding 2018 2019 2020 2021 2022 2023 2024 50M 100M 150M 200M 250M
MRVI Yearly Total Debt VS Total AssetsMRVI Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2018 2019 2020 2021 2022 2023 2024 500M 1B 1.5B 2B

2.2 Solvency

Based on the Altman-Z score of 0.90, we must say that MRVI is in the distress zone and has some risk of bankruptcy.
MRVI's Altman-Z score of 0.90 is in line compared to the rest of the industry. MRVI outperforms 44.44% of its industry peers.
A Debt/Equity ratio of 1.20 is on the high side and indicates that MRVI has dependencies on debt financing.
The Debt to Equity ratio of MRVI (1.20) is worse than 79.63% of its industry peers.
Industry RankSector Rank
Debt/Equity 1.2
Debt/FCF N/A
Altman-Z 0.9
ROIC/WACCN/A
WACC12.02%
MRVI Yearly LT Debt VS Equity VS FCFMRVI Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2018 2019 2020 2021 2022 2023 2024 0 200M 400M

2.3 Liquidity

A Current Ratio of 5.16 indicates that MRVI has no problem at all paying its short term obligations.
MRVI has a better Current ratio (5.16) than 74.07% of its industry peers.
A Quick Ratio of 4.49 indicates that MRVI has no problem at all paying its short term obligations.
Looking at the Quick ratio, with a value of 4.49, MRVI is in the better half of the industry, outperforming 72.22% of the companies in the same industry.
Industry RankSector Rank
Current Ratio 5.16
Quick Ratio 4.49
MRVI Yearly Current Assets VS Current LiabilitesMRVI Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2018 2019 2020 2021 2022 2023 2024 200M 400M 600M 800M

More info and screens

2

3. Growth

3.1 Past

The earnings per share for MRVI have decreased strongly by -1100.00% in the last year.
The Revenue for MRVI has decreased by -22.53% in the past year. This is quite bad
Measured over the past years, MRVI shows a quite strong growth in Revenue. The Revenue has been growing by 12.61% on average per year.
EPS 1Y (TTM)-1100%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-391.94%
Revenue 1Y (TTM)-22.53%
Revenue growth 3Y-31.3%
Revenue growth 5Y12.61%
Sales Q2Q%-35.43%

3.2 Future

MRVI is expected to show a very negative growth in Earnings Per Share. In the coming years, the EPS will decrease by -20.59% yearly.
MRVI is expected to show a small growth in Revenue. In the coming years, the Revenue will grow by 0.36% yearly.
EPS Next Y-219.51%
EPS Next 2Y-48.49%
EPS Next 3Y-10%
EPS Next 5Y-20.59%
Revenue Next Year-26.29%
Revenue Next 2Y-11.09%
Revenue Next 3Y-4.87%
Revenue Next 5Y0.36%

3.3 Evolution

When comparing the Revenue growth rate of the last years to the growth rate of the upcoming years, we see that the growth is decreasing.
MRVI Yearly Revenue VS EstimatesMRVI Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 2032 200M 400M 600M 800M
MRVI Yearly EPS VS EstimatesMRVI Yearly EPS VS EstimatesYearly EPS VS Estimates 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 0 0.5 1 1.5

More info and screens

0

4. Valuation

4.1 Price/Earnings Ratio

The Price/Earnings Ratio is negative for MRVI. In the last year negative earnings were reported.
Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for MRVI. No positive earnings are expected for the next year.
Industry RankSector Rank
PE N/A
Fwd PE N/A
MRVI Price Earnings VS Forward Price EarningsMRVI Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 40

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
MRVI Per share dataMRVI EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 0.2 -0.2 0.4 0.6 0.8 1

4.3 Compensation for Growth

MRVI's earnings are expected to decrease with -10.00% in the coming years. This may justify a cheaper valuation.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y-48.49%
EPS Next 3Y-10%

More info and screens

0

5. Dividend

5.1 Amount

No dividends for MRVI!.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

MARAVAI LIFESCIENCES HLDGS-A

NASDAQ:MRVI (8/28/2025, 8:27:26 PM)

After market: 2.38 0 (0%)

2.38

+0.05 (+2.15%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryLife Sciences Tools & Services
Earnings (Last)08-11 2025-08-11/amc
Earnings (Next)11-05 2025-11-05/amc
Inst Owners74.61%
Inst Owner Change-0.14%
Ins Owners5.58%
Ins Owner Change69.4%
Market Cap607.76M
Analysts76.67
Price Target4.21 (76.89%)
Short Float %12.24%
Short Ratio7.44
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)0
Avg EPS beat(2)-10.2%
Min EPS beat(2)-10.61%
Max EPS beat(2)-9.8%
EPS beat(4)0
Avg EPS beat(4)-55.61%
Min EPS beat(4)-154.98%
Max EPS beat(4)-9.8%
EPS beat(8)2
Avg EPS beat(8)-46.33%
EPS beat(12)4
Avg EPS beat(12)-39.93%
EPS beat(16)8
Avg EPS beat(16)-25.3%
Revenue beat(2)1
Avg Revenue beat(2)1.24%
Min Revenue beat(2)-1.9%
Max Revenue beat(2)4.37%
Revenue beat(4)1
Avg Revenue beat(4)-1.55%
Min Revenue beat(4)-5.38%
Max Revenue beat(4)4.37%
Revenue beat(8)4
Avg Revenue beat(8)-0.27%
Revenue beat(12)4
Avg Revenue beat(12)-1.33%
Revenue beat(16)7
Avg Revenue beat(16)-0.22%
PT rev (1m)-30.87%
PT rev (3m)-29.32%
EPS NQ rev (1m)-18.83%
EPS NQ rev (3m)-430.4%
EPS NY rev (1m)-9.27%
EPS NY rev (3m)-12.45%
Revenue NQ rev (1m)-2.58%
Revenue NQ rev (3m)-27.21%
Revenue NY rev (1m)-1.58%
Revenue NY rev (3m)-1.16%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 2.82
P/FCF N/A
P/OCF N/A
P/B 2.29
P/tB N/A
EV/EBITDA N/A
EPS(TTM)-0.24
EYN/A
EPS(NY)-0.22
Fwd EYN/A
FCF(TTM)-0.18
FCFYN/A
OCF(TTM)-0.08
OCFYN/A
SpS0.85
BVpS1.04
TBVpS-0.22
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -21.71%
ROE -73.24%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM 29.11%
FCFM N/A
ROA(3y)-4.24%
ROA(5y)0.56%
ROE(3y)-10.9%
ROE(5y)22.38%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-20.26%
GM growth 5Y-4.76%
F-Score4
Asset Turnover0.24
Health
Industry RankSector Rank
Debt/Equity 1.2
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 38.12%
Cap/Sales 11.14%
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 5.16
Quick Ratio 4.49
Altman-Z 0.9
F-Score4
WACC12.02%
ROIC/WACCN/A
Cap/Depr(3y)80.93%
Cap/Depr(5y)80.31%
Cap/Sales(3y)12.22%
Cap/Sales(5y)9.49%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-1100%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-391.94%
EPS Next Y-219.51%
EPS Next 2Y-48.49%
EPS Next 3Y-10%
EPS Next 5Y-20.59%
Revenue 1Y (TTM)-22.53%
Revenue growth 3Y-31.3%
Revenue growth 5Y12.61%
Sales Q2Q%-35.43%
Revenue Next Year-26.29%
Revenue Next 2Y-11.09%
Revenue Next 3Y-4.87%
Revenue Next 5Y0.36%
EBIT growth 1Y-148.83%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year-1789.58%
EBIT Next 3Y65.83%
EBIT Next 5Y118.38%
FCF growth 1Y-116.86%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-106.74%
OCF growth 3Y-72.74%
OCF growth 5Y-20.9%